

Biogen: Teriflunomide Does Not TOWER Over BG-12!

<https://marketpublishers.com/r/BDDC0F10890EN.html>

Date: May 2012

Pages: 4

Price: US\$ 90.00 (Single User License)

ID: BDDC0F10890EN

Abstracts

Top-line data from PhIII trial, TOWER of Sanofi's Aubagio (teriflunomide, R, RRMS, PDUFA: 3Q12) reaffirms our take on BG-12 (Dimethyl fumarate, R, Est. PDUFA: Dec. 2012) being the best amongst the oral treatment options for RRMS. EMEA and US FDA's concerns on safety resulted in updated label -risk of Novartis' Gilenya is a positive for BG-12 due to later having better safety profile. Other catalysts includes data from pivotal trial of Hemophilia compounds and PhIII data from Dexamprimoexole in ALS will keep stock volatile in 2012 ... For more details, please read our report released on June 1st , 2012 on Biogen (BIIB), titled "Teriflunomide Does Not TOWER Over BG-12"

Contents

COMPANIES MENTIONED

Biogen Idec

I would like to order

Product name: Biogen: Teriflunomide Does Not TOWER Over BG-12!

Product link: <https://marketpublishers.com/r/BDDC0F10890EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BDDC0F10890EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970